Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Public ClinicalTrials.gov record NCT04905407. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction Therapy
Study identification
- NCT ID
- NCT04905407
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Syros Pharmaceuticals
- Industry
- Enrollment
- 66 participants
Conditions and interventions
Conditions
Interventions
- Azacitidine Drug
- Tamibarotene Drug
- Venetoclax Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 25, 2021
- Primary completion
- Aug 11, 2024
- Completion
- Aug 11, 2024
- Last update posted
- Feb 23, 2025
2021 – 2024
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | — |
| UCLA Medical Center Division of Hematology/Oncology | Los Angeles | California | 90095 | — |
| University of Colorado | Denver | Colorado | 80204 | — |
| Sarah Cannon Research Institute at Colorado Blood Cancer Institute | Denver | Colorado | 80218 | — |
| Hartford HealthCare | Hartford | Connecticut | 06102 | — |
| Northside | Atlanta | Georgia | 30342 | — |
| University of Mississippi | Jackson | Mississippi | 39213 | — |
| HCA Midwest Research Medical Center | Kansas City | Missouri | 64132 | — |
| Atlantic Health | Morristown | New Jersey | 07960 | — |
| Roswell Park Comprehensive Cancer Center | Buffalo | New York | 14263 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Novant Health | Charlotte | North Carolina | 28204 | — |
| The Ohio State University James Cancer Hospital | Columbus | Ohio | 43210 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04905407, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 23, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04905407 live on ClinicalTrials.gov.